Your browser doesn't support javascript.
Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies.
Dobaño, Carlota; Santano, Rebeca; Jiménez, Alfons; Vidal, Marta; Chi, Jordi; Rodrigo Melero, Natalia; Popovic, Matija; López-Aladid, Rubén; Fernández-Barat, Laia; Tortajada, Marta; Carmona-Torre, Francisco; Reina, Gabriel; Torres, Antoni; Mayor, Alfredo; Carolis, Carlo; García-Basteiro, Alberto L; Aguilar, Ruth; Moncunill, Gemma; Izquierdo, Luis.
  • Dobaño C; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain; Spanish Consortium for Research in Epidemiology and Public Health (CIBERESP), Spain. Electronic address: Carlota.dobano@isglobal.org.
  • Santano R; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Jiménez A; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain; Spanish Consortium for Research in Epidemiology and Public Health (CIBERESP), Spain.
  • Vidal M; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Chi J; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Rodrigo Melero N; Biomolecular Screening and Protein Technologies Unit, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Popovic M; Biomolecular Screening and Protein Technologies Unit, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • López-Aladid R; Cellex Laboratory, CibeRes (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, 06/06/0028), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic, Barcelona, Spain.
  • Fernández-Barat L; Cellex Laboratory, CibeRes (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, 06/06/0028), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic, Barcelona, Spain.
  • Tortajada M; Occupational Health Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
  • Carmona-Torre F; Infectious Diseases Division and Clinical Microbiology, Clínica Universidad de Navarra, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Spain.
  • Reina G; Clínica Universidad de Navarra, Navarra Institute for Health Research, Pamplona, Spain.
  • Torres A; Cellex Laboratory, CibeRes (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, 06/06/0028), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic, Barcelona, Spain; Pneumology Service, Hospital Clinic, Barcelona, Spain.
  • Mayor A; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain; Spanish Consortium for Research in Epidemiology and Public Health (CIBERESP), Spain; Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
  • Carolis C; Biomolecular Screening and Protein Technologies Unit, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • García-Basteiro AL; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain; Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique; International Health Department, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain.
  • Aguilar R; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Moncunill G; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain. Electronic address: Gemma.moncunill@isglobal.org.
  • Izquierdo L; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain.
Transl Res ; 232: 60-74, 2021 06.
Article in English | MEDLINE | ID: covidwho-1081356
Semantic information from SemMedBD (by NLM)
1. Measles Virus Nucleoprotein PART_OF 2019 novel coronavirus
Subject
Measles Virus Nucleoprotein
Predicate
PART_OF
Object
2019 novel coronavirus
2. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
3. Antibodies TREATS Persons
Subject
Antibodies
Predicate
TREATS
Object
Persons
4. Negative PROCESS_OF Persons
Subject
Negative
Predicate
PROCESS_OF
Object
Persons
5. 2019 novel coronavirus PROCESS_OF Persons
Subject
2019 novel coronavirus
Predicate
PROCESS_OF
Object
Persons
6. Antibodies TREATS Symptoms
Subject
Antibodies
Predicate
TREATS
Object
Symptoms
7. Antibodies TREATS Borg Category-Ratio 10 Perceived Exertion Score 5
Subject
Antibodies
Predicate
TREATS
Object
Borg Category-Ratio 10 Perceived Exertion Score 5
8. Symptoms PROCESS_OF Patients
Subject
Symptoms
Predicate
PROCESS_OF
Object
Patients
9. Borg Category-Ratio 10 Perceived Exertion Score 5 PROCESS_OF Patients
Subject
Borg Category-Ratio 10 Perceived Exertion Score 5
Predicate
PROCESS_OF
Object
Patients
10. Antibodies TREATS Patients
Subject
Antibodies
Predicate
TREATS
Object
Patients
11. Measles Virus Nucleoprotein PART_OF 2019 novel coronavirus
Subject
Measles Virus Nucleoprotein
Predicate
PART_OF
Object
2019 novel coronavirus
12. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
13. Antibodies TREATS Persons
Subject
Antibodies
Predicate
TREATS
Object
Persons
14. Negative PROCESS_OF Persons
Subject
Negative
Predicate
PROCESS_OF
Object
Persons
15. 2019 novel coronavirus PROCESS_OF Persons
Subject
2019 novel coronavirus
Predicate
PROCESS_OF
Object
Persons
16. Antibodies TREATS Symptoms
Subject
Antibodies
Predicate
TREATS
Object
Symptoms
17. Antibodies TREATS Borg Category-Ratio 10 Perceived Exertion Score 5
Subject
Antibodies
Predicate
TREATS
Object
Borg Category-Ratio 10 Perceived Exertion Score 5
18. Symptoms PROCESS_OF Patients
Subject
Symptoms
Predicate
PROCESS_OF
Object
Patients
19. Borg Category-Ratio 10 Perceived Exertion Score 5 PROCESS_OF Patients
Subject
Borg Category-Ratio 10 Perceived Exertion Score 5
Predicate
PROCESS_OF
Object
Patients
20. Antibodies TREATS Patients
Subject
Antibodies
Predicate
TREATS
Object
Patients
ABSTRACT
COVID-19 patients elicit strong responses to the nucleocapsid (N) protein of SARS-CoV-2 but binding antibodies are also detected in prepandemic individuals, indicating potential crossreactivity with common cold human coronaviruses (HCoV) and questioning its utility in seroprevalence studies. We investigated the immunogenicity of the full-length and shorter fragments of the SARS-CoV-2 N protein, and the crossreactivity of antibodies with HCoV. We identified a C-terminus region in SARS-CoV2 N of minimal sequence homology with HCoV that was more specific for SARS-CoV-2 and highly immunogenic. IgGs to the full-length SARS-CoV-2 N also recognized N229E N, and IgGs to HKU1 N recognized SARS-CoV-2 N. Crossreactivity with SARS-CoV-2 was stronger for alpha- rather than beta-HCoV despite having less sequence identity, revealing the importance of conformational recognition. Higher preexisting IgG to OC43 N correlated with lower IgG to SARS-CoV-2 N in rRT-PCR negative individuals, reflecting less exposure and indicating a potential protective association. Antibodies to SARS-CoV-2 N were higher in patients with more severe and longer duration of symptoms and in females. IgGs remained stable for at least 3 months, while IgAs and IgMs declined faster. In conclusion, N protein is a primary target of SARS-CoV-2-specific and HCoV crossreactive antibodies, both of which may affect the acquisition of immunity to COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Coronavirus Nucleocapsid Proteins / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Randomized controlled trials Topics: Long Covid Limits: Female / Humans / Male Language: English Journal: Transl Res Journal subject: Medicine / Laboratory Techniques and procedures Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Coronavirus Nucleocapsid Proteins / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Randomized controlled trials Topics: Long Covid Limits: Female / Humans / Male Language: English Journal: Transl Res Journal subject: Medicine / Laboratory Techniques and procedures Year: 2021 Document Type: Article